Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the effects of posterior subtenon triamcinolone acetonide injection on refractory diabeticmacular edema (DME) after intravitreal bevacizumab (IVB) injection failure.
Methods: Patients with DME and central subfield thickness (CST) >300 μm who did not respond to IVB injectionswere retrospectively included. Specifically, we enrolled patients who were diagnosed with refractoryDME and who experienced an increase in CST after 1 to 2 IVB injections or no decrease after ≥3 consecutiveIVB injections. One clinician injected 20 mg of triamcinolone acetonide into the posterior subtenon space. Allpatients received ophthalmic examinations at baseline and at 2, 4, and 6 months post-baseline. Examinationsincluded Snellen visual acuity, intraocular pressure, and spectral-domain optical coherence tomography.
Results: Forty eyes of 34 patients were included. The average baseline CST was 476 μm. The average CSTdecreased to 368 μm at 2 months, 374 μm at 4 months, and 427 μm at 6 months (p < 0.001 for all results, Wilcoxonsigned-rank test). The average intraocular pressure increased from 15.50 to 16.92 mmHg at 2 monthsbut decreased to 16.30 mmHg at 4 months and 15.65 mmHg at 6 months. Logarithm of the minimum angle ofresolution visual acuity improved from 0.56 to 0.50 at 2 months (p = 0.023), 0.50 at 4 months (p = 0.083), and0.48 at 6 months (p = 0.133, Wilcoxon signed-rank test). No complications were detected.
Conclusions: Posterior subtenon triamcinolone acetonide is an effective and safe treatment for reducing CSTin DME refractory to IVB.

번역하기

참고문헌 (Reference)

1 Shimura M, "Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema" 31 : 748-754, 2011

2 Shimura M, "Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema" 33 : 740-747, 2013

3 Grover S, "Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa" 141 : 850-858, 2006

4 Matsuda S, "The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema" 28 : 166-170, 2014

5 Helm CJ, "The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis" 120 : 55-64, 1995

6 Mueller AJ, "The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure" 125 : 158-163, 1998

7 Ikeda Y, "The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa" 250 : 809-814, 2012

8 Klein R, "The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema" 91 : 1464-1474, 1984

9 Mitchell P, "The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema" 118 : 615-625, 2011

10 Bakri SJ, "Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema" 139 : 290-294, 2005